# China NMPA Drug Inspection - Jilin Shuangxing Pharmaceutical Co., Ltd. - Acanthopanax senticosus tablets

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/jilin-shuangxing-pharmaceutical-co-ltd/d83a0d10-2e4f-4a42-8616-23a3070f8510/
Source feed: China

> China NMPA drug inspection for Jilin Shuangxing Pharmaceutical Co., Ltd. published May 16, 2018. Drug: Acanthopanax senticosus tablets. The National Medical Products Administration (NMPA) issued an announcement on May 16, 2018, detailing non-compliance iss

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Announcement No. 28 of 2018 from the National Medical Products Administration regarding four batches of drugs that did not meet the requirements.
- Company Name: Jilin Shuangxing Pharmaceutical Co., Ltd.
- Publication Date: 2018-05-16
- Drug Name: Acanthopanax senticosus tablets
- Inspection Finding: Content determination did not meet the requirements
- Action Taken: Control measures such as sealing and seizure have been taken, requiring enterprises to suspend sales and use, recall products, and rectify the situation; relevant provincial drug regulatory authorities have initiated investigations into illegal activities involving the production and sale of counterfeit and substandard drugs.
- Summary: The National Medical Products Administration (NMPA) issued an announcement on May 16, 2018, detailing non-compliance issues with four batches of drugs from multiple companies. Testing conducted by various provincial institutes identified significant violations. Shaohuatang Pharmaceutical Co., Ltd. was cited for excessive sulfur dioxide residue in its Angelica dahurica product. Hubei Renyue Pharmaceutical Co., Ltd. faced issues with the content determination of its Andrographis paniculata tablets, and Jilin Shuangxing Pharmaceutical Co., Ltd. similarly failed content determination for its Acanthopanax senticosus tablets. In response, regulatory authorities implemented immediate control measures including product recall, suspension of sales and use, and asset seizure. The NMPA mandated that provincial drug regulatory authorities investigate these companies for illegal activities, including the production and sale of substandard drugs, in accordance with Articles 73, 74, and 75 of the *Drug Administration Law of the People's Republic of China*. Investigations are required to be completed, and results made public, within three months. This action underscores a commitment to public health and stringent adherence to pharmaceutical quality standards.

Company: https://www.globalkeysolutions.net/companies/jilin-shuangxing-pharmaceutical-co-ltd/15164930-890b-44b4-8751-3b29d4acdfb4/